Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Rylaze™ (asparaginase erwinia chrysanthemi [recombinant]rywn) – New orphan drug approval

The FDA announced the approval of Jazz Pharmaceuticals’ Rylaze (asparaginase erwinia chrysanthemi [recombinant]¬rywn), as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. June 30, 2021

Keytruda® (pembrolizumab) – Indication withdrawal

Merck announced that the company plans to voluntarily withdraw the accelerated approval indication for Keytruda (pembrolizumab) July 1, 2021

Solosec® (secnidazole) – New indication

Lupin Pharmaceuticals announced the FDA approval of Solosec (secnidazole), for the treatment of trichomoniasis caused by Trichomonas vaginalis (T. vaginalis) in adults. July 1, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.